← Back to Search

eltrombopag olamine for Acute Myeloid Leukemia

Phase 2
Waitlist Available
Led By Sudipto Mukherjee, MD, PhD, MPH
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 5 year follow-up
Awards & highlights

Study Summary

This trial looks at how well a drug works in improving the recovery of platelet counts in older patients with Acute Myeloid Leukemia undergoing induction chemotherapy.

Eligible Conditions
  • Acute Myeloid Leukemia
  • Acute Basophilic Leukemia
  • Megakaryoblastic Leukemia
  • Monoblastic Leukemia
  • Monocytic Leukemia
  • Adult Acute Myeloid Leukemia
  • Acute Myelomonocytic Leukemia
  • Erythroleukemia
  • Acute Myeloblastic Leukemia
  • Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 5 year follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 5 year follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With a Median Platelet Count >= 50,000/uL
Secondary outcome measures
Complete Response Rate
Disease-Free Survival
Median Days of Platelet Transfusions
+10 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Supportive care (eltrombopag olamine)Experimental Treatment1 Intervention
Patients receive eltrombopag olamine by mouth (PO) daily (QD) until platelet counts reach >= 50,000/uL or for 8 weeks, whichever comes earlier. Treatment continues in the absence of unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
eltrombopag olamine
2009
Completed Phase 1
~100

Find a Location

Who is running the clinical trial?

Case Comprehensive Cancer CenterLead Sponsor
447 Previous Clinical Trials
31,323 Total Patients Enrolled
Sudipto Mukherjee, MD, PhD, MPHPrincipal InvestigatorCase Comprehensive Cancer Center

Media Library

eltrombopag olamine Clinical Trial Eligibility Overview. Trial Name: NCT02071901 — Phase 2
Acute Myeloid Leukemia Research Study Groups: Supportive care (eltrombopag olamine)
Acute Myeloid Leukemia Clinical Trial 2023: eltrombopag olamine Highlights & Side Effects. Trial Name: NCT02071901 — Phase 2
eltrombopag olamine 2023 Treatment Timeline for Medical Study. Trial Name: NCT02071901 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When was eltrombopag olamine FDA approved?

"While there is some data suggesting eltrombopag olamine is safe, efficacy has not been proven. Therefore, it received a score of 2."

Answered by AI

How many people are receiving treatment as part of this experiment?

"Unfortunately, this trial is no longer recruiting patients. It was initially posted on 8/14/2014 but the most recent edit was on 11/29/2021. However, there are 1672 other trials for leukemia, erythroblastic, acute and 25 eltrombopag olamine trials that are still enrolling patients if you're seeking an active clinical study."

Answered by AI

Are patients able to enroll in this clinical trial at this time?

"Data on clinicaltrials.gov reveals that this study is not open for recruitment at this time. The trial was initially posted on 8/14/2014 and last updated on 11/29/2021. Although this particular study isn't looking for patients right now, there are 1697 other studies which are."

Answered by AI
~3 spots leftby Mar 2025